ULTRESA (Aptalis Pharma US, Inc)
Welcome to the PulseAid listing for the ULTRESA drug offered from Aptalis Pharma US, Inc. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Aptalis Pharma US, Inc |
NON-PROPRIETARY NAME: | Pancrelipase |
SUBSTANCE NAME: | PANCRELIPASE LIPASE; PANCRELIPASE PROTEASE; PANCRELIPASE AMYLASE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | |
ROUTE: | ORAL |
DOSAGE FORM: | CAPSULE, DELAYED RELEASE |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2012-03-01 |
END MARKETING DATE: | 0000-00-00 |
ULTRESA HUMAN PRESCRIPTION DRUG Details:
Item Description | ULTRESA from Aptalis Pharma US, Inc |
LABELER NAME: | Aptalis Pharma US, Inc |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 13800; 27600; 27600([USP’U]/1; [USP’U]/1; [USP’U]/1) |
START MARKETING DATE: | 2012-03-01 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 58914-003_e10091e4-71b9-47bd-a6e1-1b53de27430f |
PRODUCT NDC: | 58914-003 |
APPLICATION NUMBER: | NDA022222 |
Other PANCRELIPASE LIPASE; PANCRELIPASE PROTEASE; PANCRELIPASE AMYLASE Pharmaceutical Manufacturers / Labelers: